| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Medicine |
From the Departments of Pharmacology (L.A.C., D.A.P., J.V.B.) and Pediatrics (C.B.B.), Vanderbilt University Medical Center, Nashville, Tenn.
Correspondence to Joey V. Barnett, PhD, Department of Pharmacology, Vanderbilt University Medical Center, Room 476 RRB, 2220 Pierce Ave, Nashville, TN 37232-6600. E-mail joey.barnett{at}vanderbilt.edu
Transforming growth factor (TGF)ß receptor III (TGFßR3), or ß-glycan, binds all 3 TGFß ligands and inhibin with high affinity but lacks the serine/threonine kinase domain found in the type I and type II receptors (TGFßR1, TGFßR2). TGFßR3 facilitates signaling via TGFßR1/TGFßR2 but also has been suggested to play a unique and nonredundant role in TGFß signaling. Targeted deletion of Tgfbr3 revealed a requirement for Tgfbr3 during development of the coronary vessels. Coronary vasculogenesis is significantly impaired in null mice, with few vessels evident and numerous, persistent blood islands found throughout the epicardium. Tgfbr3-null mice die at embryonic day 14.5, the time when functional coronary vasculature is required for embryo viability. However, in null mice nascent coronary vessels attach to the aorta, form 2 coronary ostia, and initiate smooth muscle recruitment by embryonic day 14. Analysis of earlier developmental stages revealed defects in the epicardium. At embryonic day 13.5, these defects include an irregular and hypercellular epicardium with abundant subepicardial mesenchyme and a thin compact zone myocardium. Tgfbr3-null mice also displayed other defects in coronary development, including dysmorphic and distended vessels along the atrioventricular groove and subepicardial hemorrhage. In null mice, vessels throughout the yolk sac and embryo form and recruit smooth muscle in a pattern indistinguishable from heterozygous or wild-type littermates. These data demonstrate a requirement for Tgfbr3 during coronary vessel development that is essential for embryonic viability.
Key Words: coronary vessels transforming growth factor ß receptor mice, null
This article has been cited by other articles:
![]() |
T. Santiago-Sim, S. Mathew-Joseph, H. Pannu, D. M. Milewicz, C. E. Seidman, J.G. Seidman, and D. H. Kim Sequencing of TGF-{beta} Pathway Genes in Familial Cases of Intracranial Aneurysm Stroke, May 1, 2009; 40(5): 1604 - 1611. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Townsend, J. L. Wrana, G. E. Davis, and J. V. Barnett Transforming Growth Factor-{beta}-stimulated Endocardial Cell Transformation Is Dependent on Par6c Regulation of RhoA J. Biol. Chem., May 16, 2008; 283(20): 13834 - 13841. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hempel, T. How, S. J. Cooper, T. R. Green, M. Dong, J. A. Copland, C. G. Wood, and G. C. Blobe Expression of the type III TGF-{beta} receptor is negatively regulated by TGF-{beta} Carcinogenesis, May 1, 2008; 29(5): 905 - 912. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Kirkbride, T. A. Townsend, M. W. Bruinsma, J. V. Barnett, and G. C. Blobe Bone Morphogenetic Proteins Signal through the Transforming Growth Factor-{beta} Type III Receptor J. Biol. Chem., March 21, 2008; 283(12): 7628 - 7637. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |